Title : Differential endocrine responses to rosiglitazone therapy in new mouse models of type 2 diabetes.

Pub. Date : 2006 Feb

PMID : 16254032






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 In summary, longitudinal profiling of multiple plasma analytes identified PAI-1 as a useful biomarker to monitor for differential pharmacogenetic responses to Rosi in these new mouse models of T2D. Rosiglitazone serine (or cysteine) peptidase inhibitor, clade E, member 1 Mus musculus